Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489520 | 1.00 | MME (0.58) | MMEAPAF1 | |
| SCHEMBL4118085 | 1.00 | MME (0.58) | MMEAPAF1 | |
| SCHEMBL976204 | 1.00 | MME (0.58) | MMEAPAF1 | |
| SCHEMBL9119146 | 0.80 | APAF1 (0.56) | MMEAPAF1 | |
| SCHEMBL9119155 | 0.80 | APAF1 (0.56) | MMEAPAF1 | |
| SCHEMBL23360816 | 0.78 | APAF1 (0.54) | MMEAPAF1 | |
| SCHEMBL11437811 | 0.76 | APAF1 (0.51) | MMEAPAF1 | |
| SCHEMBL28439487 | 0.74 | APAF1 (0.54) | MMEAPAF1 | |
| SCHEMBL29384844 | 0.74 | MME (1.00) | MME | |
| SCHEMBL7314977 | 0.74 | MME (1.00) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090176848-A1 | FORTIFIER | TORAY INDUSTRIES, INC., A CORPORATION OF JAPAN (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20060217421-A1 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1627638-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | MME 5/4885APAF1 2098/4885 |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885APAF1 1472/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | MME 4/4885APAF1 2481/4885 |
| US-20090176848-A1 | FORTIFIER | REN, ACE, PTGER1 | MME 200/4885APAF1 1105/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885APAF1 702/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885APAF1 1472/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 5/4885APAF1 2318/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | MME 13/4885APAF1 2700/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | MME 1/4885APAF1 1891/4885 |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | AGTR1, REN, AGTR2 | MME 4/4885APAF1 1967/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885APAF1 677/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885APAF1 677/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885APAF1 1452/4885 |
| US-20060217421-A1 | Fortifier | REN, PTGER1, GPR132 | MME 142/4885APAF1 1521/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885APAF1 1381/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885APAF1 1472/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | MME 6/4885APAF1 2240/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | MME 1/4885APAF1 1275/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885APAF1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.